Core Viewpoint - Kingstone Pharmaceuticals (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its Diclofenac Sodium Sustained-release Tablets (0.1g) after passing the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved Diclofenac Sodium Sustained-release Tablets are indicated for the relief of various chronic arthritis conditions, including rheumatoid arthritis, osteoarthritis, spondyloarthritis, gouty arthritis, and rheumatic arthritis during acute episodes or persistent joint pain [1] - The product is also indicated for various soft tissue rheumatic pains such as shoulder pain, tenosynovitis, bursitis, myalgia, and pain from sports injuries [1] - Additionally, it is indicated for acute mild to moderate pain, including pain following surgery, trauma, or strain, as well as primary dysmenorrhea, toothache, and headache [1]

Core Viewpoint - Kingstone Pharmaceuticals (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd. (referred to as "Deer Pharmaceutical"), has received approval from the National Medical Products Administration for its supplemental drug application for Diclofenac Sodium Sustained-release Tablets (0.1g specification), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved Diclofenac Sodium Sustained-release Tablets are indicated for the relief of various chronic arthritis conditions, including rheumatoid arthritis, osteoarthritis, spondyloarthritis, gouty arthritis, and rheumatic arthritis during acute episodes or persistent joint pain symptoms [1] - The product is also indicated for various soft tissue rheumatic pain such as shoulder pain, tenosynovitis, bursitis, myalgia, and pain from sports injuries [1] - Additionally, it is used for acute mild to moderate pain, including pain following surgery, trauma, or strain, as well as primary dysmenorrhea, toothache, and headache [1]

Core Viewpoint - The company Jinshi Yao (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Di'er Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Diclofenac Sodium Sustained-release Tablets (0.1g), which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Diclofenac Sodium Sustained-release Tablets are indicated for the relief of various chronic arthritis conditions, including rheumatoid arthritis, osteoarthritis, spondyloarthritis, gouty arthritis, and rheumatic arthritis during acute episodes or persistent joint pain [1] - The tablets are also indicated for various soft tissue rheumatic pain, such as shoulder pain, tenosynovitis, bursitis, myalgia, and pain from sports injuries [1] - Additionally, the product is suitable for acute mild to moderate pain, including pain following surgery, trauma, or strain, as well as primary dysmenorrhea, toothache, and headache [1]

Core Viewpoint - The announcement indicates that the subsidiary Zhejiang Di'er Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation of quality and efficacy for its Diclofenac Sodium Sustained-release Tablets (0.1g specification) [1] Group 1: Product Approval - The drug registration standard number is YBH28882025, and the original drug approval number is National Drug Standard H20083921 [1] - The marketing authorization holder, Zhejiang Di'er Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration [1] - The notice number for the drug supplementary application approval is 2025B05105 [1]

Core Viewpoint - Jinsiyaya Pharmaceutical (300434) announced that its wholly-owned subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Diclofenac Sodium Sustained-Release Tablets (0.1g specification), which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - Jinsiyaya Pharmaceutical's subsidiary, Zhejiang Deer Pharmaceutical, has successfully obtained a drug supplement application approval notice [1] - The approved product is Diclofenac Sodium Sustained-Release Tablets, indicating a significant milestone in the company's product portfolio [1] - The approval reflects the company's commitment to meeting regulatory standards and enhancing its market position in the pharmaceutical industry [1]

Group 1 - The core event involves a block trade of 1 million shares of Jinshi Yiyao, with a transaction value of 9.9 million yuan, accounting for 3.29% of the total trading volume on that day [1] - The transaction price was 9.9 yuan per share, which represents an 11.61% discount compared to the market closing price of 11.2 yuan [1] - The trade occurred on November 3, 2025, and was executed by Guotai Junan Securities, with both the buyer and seller being the same brokerage firm [2]

Core Viewpoint - Jinshi Yao (300434) has shown a positive market performance with a closing price of 10.98 yuan, reflecting a 4.87% increase as of October 31, 2025, indicating investor confidence and potential growth opportunities in the company [1]. Group 1: Company Operations - Jinshi Yao has established two subsidiaries in Hainan Province: Hainan Asia Pharmaceutical Co., Ltd. and Hainan Kuaike Pharmaceutical Co., Ltd. [2][3] - The company is actively monitoring the policies of the Hainan Free Trade Zone, which includes industry support, tariff reductions, tax incentives, and talent introduction, to leverage potential business opportunities and explore new growth points [2]. Group 2: Market Activity - On October 31, 2025, the net inflow of main funds into Jinshi Yao was 36.17 million yuan, indicating strong interest from major investors [3]. - Retail investors showed a net outflow of 38.54 million yuan, suggesting a divergence in investment sentiment between institutional and retail investors [3].

Group 1 - The company Jinshi Yiyao (SZ 300434) announced that board member Zheng Zhiyong plans to reduce his holdings by up to approximately 930,000 shares, representing 0.23% of the total share capital, within three months after the announcement [1] - Shareholder Jiang Erchen, who holds about 230,000 shares (0.06% of total share capital), also plans to reduce his holdings by the same amount within the same timeframe [1] - As of the announcement, Jinshi Yiyao's market capitalization is 4.3 billion yuan [1] Group 2 - For the first half of 2025, Jinshi Yiyao's revenue composition is as follows: 82.76% from the pharmaceutical manufacturing industry, 14.09% from the machinery manufacturing industry, and 3.16% from real estate leasing and management [1]

证券代码：300434 证券简称：金石亚药 公告编号：2025-042 四川金石亚洲医药股份有限公司 关于董事、股东减持股份的预披露公告 公司董事郑志勇先生、股东姜二晨先生保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 公司董事郑志勇先生，持有本公司股份3,705,304股（占本公司总股本比例 0.92%）计划在减持计划公告之日起十五个交易日后的三个月内以集中竞价交易 或大宗交易方式，减持所持有的本公司股份不超过926,326股（占本公司总股本 比例0.23%）。 公司股东姜二晨先生，持有本公司股份227,000股（占本公司总股本比例 0.06%）计划在减持计划公告之日起十五个交易日后的三个月内以集中竞价交易 或大宗交易方式，减持所持有的本公司股份不超过227,000股（占本公司总股本 比例0.06%）。姜二晨先生为公司持股5%以上股东楼金先生的一致行动人。 四川金石亚洲医药股份有限公司（以下简称"公司"）于近日收到公司董事 郑志勇先生、股东姜二晨先生出具的《关于拟减持四川金石亚洲医药股份有限 ...

Core Points - The stock price of Jinshi Asia Pharmaceutical has decreased by 2.04% on October 29, trading at 10.58 CNY per share with a market capitalization of 4.25 billion CNY [1] - The company has experienced a year-to-date stock price increase of 29.32%, but has seen a decline of 9.26% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Jinshi Asia Pharmaceutical reported a revenue of 708 million CNY, a year-on-year decrease of 6.37%, while the net profit attributable to shareholders increased by 66.47% to 96.77 million CNY [2] - The company's main business revenue composition includes 82.76% from pharmaceutical sales, 14.09% from production line and related sales, and 3.16% from property leasing and management [2] Shareholder Information - As of September 30, the number of shareholders for Jinshi Asia Pharmaceutical is 23,200, an increase of 1.72% from the previous period, with an average of 14,757 circulating shares per shareholder, a decrease of 1.69% [2] Dividend Distribution - Since its A-share listing, Jinshi Asia Pharmaceutical has distributed a total of 170 million CNY in dividends, with 71.91 million CNY distributed over the past three years [3]